mRNA Vaccine and Therapeutics Market Industry Trends and Global Forecasts to 2035, by Application Area, Target Disease Indication (Influenza, Respiratory Syncytial Virus Infection and Cytomegalovirus Diseases) and Geographical Regions

The global mRNA vaccine and therapeutics market is estimated to be worth USD 1.99 billion by 2035, primarily driven by the anticipated approval of mRNA vaccines and therapeutics intended for the treatment of infectious diseases.

The market sizing and opportunity analysis has been segmented across the following parameters:

Application Area

COVID-19
Other Indications

Target Disease Indication

Influenza
Respiratory Syncytial Virus Infection
Cytomegalovirus Diseases

Key Geographical Regions

North America
Europe
Asia-Pacific
Latin America
Rest of the World

mRNA Vaccine and Therapeutics Market: Growth and Trends

Messenger ribonucleic acid (mRNA) is a form of single-stranded ribonucleic acid (RNA) that is crucial role in transferring genetic information for protein production. The mRNA carries the coding instructions for protein synthesis from a DNA strand to the ribosomes, where these instructions are translated and processed into functional proteins.

In recent years, mRNA technology has revolutionized the pharmaceutical industry to prevent and treat a wide array of diseases and disorders. The success of COVID-19 vaccines has paved the path for mRNA vaccines and therapeutics. It is worth highlighting that, in the past few years, more than 170 clinical trials related to mRNA-based therapeutics / vaccines have been registered. Multiple preclinical and clinical studies show the efficacy of these platforms which have been published in the last two years across different research articles. This demonstrates the extensive development efforts being undertaken by stakeholders in this domain. At present, over 45 industry players are engaged in the development of mRNA drug candidates for a wide range of disease indications.

The success of COVID-19 vaccines, growing research activity and the rich pipeline of mRNA drug candidates is likely to drive the global mRNA vaccine and therapeutics market in the coming decade.

mRNA Vaccine and Therapeutics Market: Key Insights

The report delves into the current state of the mRNA vaccine and therapeutics market and identifies potential growth opportunities within the industry. Some key findings from the report include:

Presently, over 235 mRNA drug candidates are available in the market or under development; majority of these drug candidates are vaccines using lipid nanoparticles as delivery systems.
The pipeline features several drugs, which are being investigated across different phases of development; 60% of the drug candidates are designed to be administered via intramuscular routes.
The current market landscape of mRNA vaccine and therapeutics developers is fragmented, featuring the presence of both new entrants and established players; majority of these players are based in the US.
Stakeholders are actively upgrading their existing capabilities to further enhance their respective product pipeline and comply with the evolving industry benchmarks.
The growing interest of stakeholders is evident from the surge in partnership activity; clinical trial agreements emerged as the most prevalent partnership model adopted by drug developers.
Several investors, having realized the opportunity within this upcoming segment, have invested over USD 11 billion across various funding rounds.
More than 345,000 patients have been recruited / enrolled in clinical trials registered for various mRNA-based therapies, across different geographies.
Over 430 patents related to mRNA vaccine and therapeutics have been filed / granted by industry and non-industry stakeholders, indicating the growing intellectual capital in this domain.
Big pharma players have undertaken several initiatives, ranging from proprietary product development to strategic investments, to tap the lucrative opportunity in this rapidly growing market.
The projected opportunity for mRNA vaccine and therapeutics market is likely to be driven by the increasing research and development for mRNA-based drugs focused on non-COVID indications.

mRNA Vaccine and Therapeutics Market: Key Segments

Several indications, such as Influenza, Respiratory Syncytial Virus, Cytomegalovirus, are the Expected to Drive the mRNA Vaccine and Therapeutics Market

Based on the application area, the market is segmented into COVID-19 and other indications. Owing to their proven efficacy against the COVID-19 infection, the vaccines and therapeutics developed for COVID-19 infection have captured the majority of the market share. However, the anticipated approval of mRNA vaccines for other indications is likely to drive the market in the coming decade.

Currently, Influenza Segment Occupies the Largest Share of the mRNA Vaccine and Therapeutics Market

Based on the target disease indication, the market is segmented into influenza, respiratory syncytial virus infection and cytomegalovirus diseases. It is worth highlighting that the vaccines and therapeutics developed for influenza are likely to drive the market in the coming decade. This can be attributed to the rise in investment in the research and development of influenza vaccines, along with growing awareness among governments and non-profit organizations about the importance of influenza prevention and control.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific, Latin America and Rest of the World. It is worth highlighting that the market for North America holds the maximum share of the mRNA vaccines and therapeutics market. This trend is likely to remain the same in the coming decade.

Some Key Players in the mRNA Vaccine and Therapeutics Market include:

Arcturus Therapeutics
BioNTech
CureVac
Ethris
IMMORNA
Moderna
Providence Therapeutics
RNACure
Suzhou Abogen Biosciences
Turn Biotechnologies
Gennova
Innovac Therapeutics
Kernal Biologics
Pantherna Therapeutics
pHion Therapeutics
Recode Therapeutics
Rejuvenation Technologies
RNAimmune
Strand Therapeutics
Walvax
Ziphius Vaccines

Primary Research Overview

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

Business Development Manager, Canvax
Senior Director, Business Development, eTheRNA
Team Leader, GC Biopharma

mRNA Vaccine and Therapeutics Market: Research Coverage

Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the mRNA vaccine and therapeutics market, focusing on key market segments, including [A] application area, [B] target disease indication and [C] key geographical regions.
Market Landscape (Drug Therapies): A comprehensive evaluation of mRNA therapeutics and vaccines, considering various parameters, such as [A] phase of development, [B] type of drug candidate, [C] therapeutic area, [D] type of delivery system, [E] type of molecule encoded and [F] route of administration.
Market Landscape (Drug Developers): A comprehensive evaluation of companies involved in the development of mRNA vaccine and therapeutics, considering various parameters, such as [A] year of establishment, [B] company size (in terms of number of employees), [C] location of headquarters, [D] regional landscape and [E] key players engaged in this domain.
Company Competitiveness Analysis: A comprehensive competitive analysis of mRNA vaccine and therapeutic developers, examining factors such as [A] developer strength, [B] pipeline strength and [C] number of therapeutic areas targeted.
Company Profiles: In-depth profiles of key industry players engaged in the development of mRNA vaccine and therapeutics, focusing on [A] company overviews, [B] financial information, [C] mRNA vaccines and therapeutics pipeline, [D] recent developments and [E] an informed future outlook.
Big Pharma Analysis: A comprehensive examination of various mRNA focused initiatives undertaken by major pharmaceutical companies. It includes a heat map representation that highlights mRNA therapeutics and vaccines under development (in partnership with core mRNA-focused entities), along with information on [A] funding amount raised, [B] partnership activity, and [C] diversity of product portfolio, as well as a spider web representation, comparing the initiatives of big pharmaceutical players on the basis of multiple relevant parameters.
Start-up Health Indexing: An analysis of the startup companies engaged in this domain based on several relevant parameters, such as [A] number of candidates in discovery, [B] preclinical and clinical phases of development. In addition, it provides details on amount raised, number of investors and number of deals inked.
Clinical Trial Analysis: Examination of completed, ongoing, and planned clinical studies of various mRNA vaccines and therapeutics based on several relevant parameters, such as [A] trial registration year, [B] trial status, [C] trial phase, [D] therapeutic area, [E] study design, [F] type of sponsor / collaborator, [G] leading industry players (in terms of number of trials conducted), [H] enrolled patient population and [I] geography.
Partnerships and Collaborations: An analysis of partnerships established in this sector, since 2013, based on several relevant parameters, such as year of partnership, type of partnership, therapeutic area, most active players (in terms of number of deals inked) and regional distribution of partnership activity.
Funding and Investment Analysis: A detailed evaluation of the investments made in the mRNA vaccines and therapeutics domain, encompassing seed financing, venture capital, IPOs, secondary offerings, debt, grants and other offerings based on several parameters, such as [A] year of funding, [B] type of funding, [C] amount invested, therapeutic area, most active players (in terms of number of funding instances and amount invested) and key investors (in terms of number of funding instances).
Patent Analysis: Detailed analysis of various patents filed / granted related to mRNA therapeutics and vaccines several relevant parameters, such as [A] type of patent, [B] publication year, [C] geographical region, [D] CPC symbols, [E] leading industry players (in terms of the number of patents filed / granted) and [F] patent valuation.
Market Impact Analysis: The report analyzes various factors such as drivers, restraints, opportunities, and challenges affecting market growth.

Key Questions Answered in this Report

How many companies are currently engaged in this market?
Which are the leading companies in this market?
What kind of partnership models are commonly adopted by industry stakeholders?
What amount has been invested in this domain?
What factors are likely to influence the evolution of this market?
What is the current and future market size?
What is the CAGR of this market?
How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

Additional Benefits

Complimentary PPT Insights Packs
Complimentary Excel Data Packs for all Analytical Modules in the Report
10% Free Content Customization
Detailed Report Walkthrough Session with Research Team
Free Updated report if the report is 6-12 months old or older

1. PREFACE

1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Research Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary Research
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Future Estimates
3.2.2. Currency Coverage and Foreign Exchange Rate
3.2.2.1. Major Currencies Affecting the Market
3.2.2.2. Factors Affecting Currency Fluctuations and Foreign Exchange Rates
3.2.2.3. Impact of Foreign Exchange Rate Volatility on the Market
3.2.2.4. Strategies for Mitigating Foreign Exchange Risks
3.2.3. Trade Policies
3.2.3.1. Impact of Trade Barriers on the Market
3.2.3.2. Strategies for Mitigating the Risks associated with Trade Barriers
3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

5.1. Chapter Overview
5.2. mRNA Therapeutics
5.2.1. Advantages of mRNA Therapeutics
5.2.2. Key Applications of mRNA Therapeutics
5.3. mRNA Vaccines
5.3.1. Advantages of mRNA Vaccines
5.3.2. Key Applications of mRNA Vaccines
5.4. mRNA Delivery Routes
5.5. mRNA Delivery Strategies
5.6. Key Challenges Associated with mRNA Vaccine and Therapeutics
5.7. Future Perspectives

6. MARKET LANDSCAPE

6.1. Chapter Overview
6.2. mRNA Vaccine and Therapeutics: Overall Market Landscape
6.2.1. Analysis by Phase of Development
6.2.2. Analysis by Type of Drug Candidate
6.2.3. Analysis by Therapeutic Area
6.2.4. Analysis by Phase of Development and Therapeutic Area
6.2.5. Analysis by Type of Delivery System
6.2.6. Analysis by Type of Molecule Encoded
6.2.7. Analysis by Route of Administration
6.2.8. Analysis by Therapeutic Area and Route of Administration
6.2.9. Analysis by Phase of Development, Therapeutic Area and Route of Administration

7. COMPETITIVE LANDSCAPE

7.1. Chapter Overview
7.2. mRNA Vaccine and Therapeutics: List of Developers
7.2.1. Analysis by Year of Establishment
7.2.2. Analysis by Company Size
7.2.3. Analysis by Location of Headquarters
7.2.4. Key Players: Analysis by Number of Drug Candidates
7.2.5. Key Players: Analysis by Phase of Development
7.2.6. Key Players: Analysis by Therapeutic Area

8. COMPANY COMPETITIVENESS ANALYSIS

8.1. Chapter Overview
8.2. Key Assumptions and Parameters
8.3. Methodology
8.4. mRNA Vaccine and Therapeutics Developers: Company Competitiveness Analysis
8.5. mRNA Vaccine and Therapeutics Developers based in North America
8.6. mRNA Vaccine and Therapeutics Developers based in Europe
8.7. mRNA Vaccine and Therapeutics Developers based in Asia-Pacific and Rest of the World

9. COMPANY PROFILES

9.1. Chapter Overview
9.2. Leading Companies in mRNA Vaccine and Therapeutics Market
9.2.1. Arcturus Therapeutics
9.2.1.1. Company Overview
9.2.1.2. Financial Information
9.2.1.3. Pipeline Overview
9.2.1.4. Recent Developments and Future Outlook
9.2.2. BioNTech
9.2.2.1. Company Overview
9.2.2.2. Financial Information
9.2.2.3. Pipeline Overview
9.2.2.4. Recent Developments and Future Outlook
9.2.3. CureVac
9.2.3.1. Company Overview
9.2.3.2. Financial Information
9.2.3.3. Pipeline Overview
9.2.3.4. Recent Developments and Future Outlook
9.2.4. Ethris
9.2.4.1. Company Overview
9.2.4.2. Pipeline Overview
9.2.4.3. Recent Developments and Future Outlook
9.2.5. Immorna
9.2.5.1. Company Overview
9.2.5.2. Pipeline Overview
9.2.5.3. Recent Developments and Future Outlook
9.2.6. Moderna
9.2.6.1. Company Overview
9.2.6.2. Financial Information
9.2.6.3. Pipeline Overview
9.2.6.4. Recent Developments and Future Outlook
9.2.7. Providence Therapeutics
9.2.7.1. Company Overview
9.2.7.2. Financial Information
9.2.7.3. Pipeline Overview
9.2.7.4. Recent Developments and Future Outlook
9.2.8. Suzhou Abogen Biosciences
9.2.8.1. Company Overview
9.2.8.2. Pipeline Overview
9.2.8.3. Recent Developments and Future Outlook
9.3. Other Leading Players in mRNA Vaccine and Therapeutics Market
9.3.1. Gennova Biopharmaceuticals
9.3.1.1. Company Overview
9.3.1.2. Pipeline Overview
9.3.2. Innovac Therapeutics
9.3.2.1. Company Overview
9.3.2.2. Pipeline Overview
9.3.3. Kernal Biologics
9.3.3.1. Company Overview
9.3.3.2. Pipeline Overview
9.3.4. Pantherna Therapeutics
9.3.4.1. Company Overview
9.3.4.2. Pipeline Overview
9.3.5. pHion Therapeutics
9.3.5.1. Company Overview
9.3.5.2. Pipeline Overview
9.3.6. Recode Therapeutics
9.3.6.1. Company Overview
9.3.6.2. Pipeline Overview
9.3.7. Rejuvenation Technologies
9.3.7.1. Company Overview
9.3.7.2. Pipeline Overview
9.3.8. RNACure
9.3.8.1. Company Overview
9.3.8.2. Pipeline Overview
9.3.9. RNAimmune
9.3.9.1. Company Overview
9.3.9.2. Pipeline Overview
9.3.10. Strand Therapeutics
9.3.10.1. Company Overview
9.3.10.2. Pipeline Overview
9.3.11. Turn Biotechnologies
9.3.11.1. Company Overview
9.3.11.2. Pipeline Overview
9.3.12. Walvax
9.3.12.1. Company Overview
9.3.12.2. Pipeline Overview
9.3.13. Ziphius Vaccines
9.3.13.1. Company Overview
9.3.13.2. Pipeline Overview

10. BIG PHARMA INITIATIVES

10.1. Chapter Overview
10.2. Scope and Methodology
10.3. mRNA Related Initiatives of Big Pharmaceutical Players
10.3.1. Analysis by Portfolio Diversity
10.3.2. Analysis by Phase of Development
10.3.3. Analysis by Target Therapeutic Area
10.4. Benchmarking Analysis: Big Pharma Players
10.4.1. Spider Web Analysis: Amgen
10.4.2. Spider Web Analysis: AstraZeneca
10.4.3. Spider Web Analysis: Bayer
10.4.4. Spider Web Analysis: BioNTech
10.4.5. Spider Web Analysis: Eli Lilly
10.4.6. Spider Web Analysis: Gilead Sciences
10.4.7. Spider Web Analysis: GlaxoSmithKline
10.4.8. Spider Web Analysis: Merck
10.4.9. Spider Web Analysis: Moderna
10.4.10. Spider Web Analysis: Novartis
10.4.11. Spider Web Analysis: Novo Nordisk
10.4.12. Spider Web Analysis: Pfizer
10.4.13. Spider Web Analysis: Roche
10.4.14. Spider Web Analysis: Sanofi
10.4.15. Spider Web Analysis: Takeda
10.5. Concluding Remarks

11. START-UP HEALTH INDEXING

11.1. Chapter Overview
11.2. Start-ups focused on mRNA Vaccine and Therapeutics
11.2.1. Analysis by Location of Headquarters
11.3. Benchmarking of Start-ups
11.4. Startup-Health Indexing
11.4.1. Analysis by Supplier Strength
11.4.2. Analysis by Pipeline Maturity
11.4.3. Analysis by Pipeline Strength
11.4.4. Analysis by Financial Investments
11.4.5. Analysis by Partnership Activity
11.4.6. Start-ups Health Indexing: Roots Analysis Perspective

12. CLINICAL TRIAL ANALYSIS

12.1. Chapter Overview
12.2. Scope and Methodology
12.3. mRNA Vaccine and Therapeutics: Clinical Trial Analysis
12.3.1. Analysis by Trial Registration Year
12.3.2. Analysis by Trial Status
12.3.3. Analysis by Trial Phase
12.3.4. Analysis by Trial Registration Year and Trial Status
12.3.5. Analysis by Trial Registration Year and Trial Phase
12.3.6. Analysis by Trial Status and Trial Phase
12.3.7. Analysis of Enrolled Patient Population by Trial Registration Year
12.3.8. Analysis by Study Design
12.3.9. Analysis by Type of Sponsor / Collaborator
12.3.10. Most Active Players: Analysis by Number of Registered Trials
12.3.11. Analysis by Therapeutic Area
12.3.12. Analysis by Number of Registered Trials and Geography
12.3.13. Analysis by Number of Registered Trials, Trial Status and Geography
12.3.14. Analysis of Enrolled Patient Population by Geography

13. PARTNERSHIPS AND COLLABORATIONS

13.1. Chapter Overview
13.2. Partnership Models
13.3. mRNA Vaccine and Therapeutics: Partnerships and Collaborations
13.3.1. Analysis by Year of Partnership
13.3.2. Analysis by Type of Partnership
13.3.3. Analysis by Year and Type of Partnership
13.3.4. Analysis by Therapeutic Area
13.3.5. Analysis by Type of Partnership and Therapeutic Area
13.3.6. Most Active Players: Analysis by Number of Partnerships
13.3.7. Analysis by Geography
13.3.7.1. Intercontinental and Intracontinental Agreements
13.3.7.2. Local and International Agreements

14. FUNDING AND INVESTMENT ANALYSIS

14.1. Chapter Overview
14.2. Types of Funding
14.3. mRNA Vaccine and Therapeutics: Funding and Investments
14.3.1. Analysis by Year of Funding
14.3.2. Analysis by Amount Invested
14.3.3. Analysis by Type of Funding
14.3.4. Analysis by Year and Type of Funding
14.3.5. Analysis of Funding Instances and Amount Invested by Therapeutic Area
14.3.6. Analysis by Geography
14.3.7. Most Active Players: Analysis by Number of Funding Instances
14.3.8. Most Active Players: Analysis by Total Amount Raised
14.3.9. Most Active Investors: Analysis by Number of Funding Instances
14.3.10. Analysis of Amount Invested by Year and Type of Funding

15. PATENT ANALYSIS

15.1. Chapter Overview
15.2. Scope and Methodology
15.3. mRNA Vaccine and Therapeutics: Patent Analysis
15.3.1. Analysis by Type of Patent
15.3.2. Analysis by Patent Publication Year
15.3.3. Analysis of Granted Patents by Publication Year
15.3.4. Analysis of Patent Applications by Publication Year
15.3.5. Analysis of Granted Patents and Patent Applications by Publication Year
15.3.6. Analysis by Publication Year and Type of Applicant
15.3.7. Analysis by Patent Issuing Authority
15.3.8. Analysis by Patent Age
15.3.9. Analysis by CPC Symbols
15.3.10. Leading Players: Analysis by Number of Patents
15.3.11. Leading Inventors: Analysis by Number of Patents
15.4. Patent Benchmarking Analysis
15.4.1. Analysis of Patent Characteristics (CPC Codes) by Leading Industry Players
15.5. mRNA Vaccine and Therapeutics: Patent Valuation Analysis

16. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

16.1. Chapter Overview
16.2. Market Drivers
16.3. Market Restraints
16.4. Market Opportunities
16.5. Market Challenges
16.6. Conclusion

17. GLOBAL mRNA VACCINE AND THERAPEUTICS MARKET

17.1. Chapter Overview
17.2. Assumptions and Methodology
17.3. Global mRNA Vaccine and Therapeutics Market, till 2035
17.3.1. Scenario Analysis
17.3.1.1. Conservative Scenario
17.3.1.2. Optimistic Scenario
17.4. Key Market Segmentations

18. mRNA VACCINE AND THERAPEUTICS MARKET, BY APPLICATION AREA

18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. mRNA Vaccine and Therapeutics Market: Distribution by Application Area, 2024, 2028 and 2035
18.3.1. mRNA Vaccine and Therapeutics Market for COVID-19, till 2035
18.3.2. mRNA Vaccine and Therapeutics Market for Other Indications, till 2035
18.4. Data Triangulation and Validation

19. mRNA VACCINE AND THERAPEUTICS MARKET, BY TARGET DISEASE INDICATION

19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. mRNA Vaccine and Therapeutics Market: Distribution by Target Disease Indication, 2026, 2030 and 2035
19.3.1. mRNA Vaccine and Therapeutics Market for Influenza, till 2035
19.3.2. mRNA Vaccine and Therapeutics Market for Respiratory Syncytial Virus Infection, till 2035
19.3.3. mRNA Vaccine and Therapeutics Market for Cytomegalovirus Disease, till 2035
19.4. Data Triangulation and Validation

20. mRNA VACCINE AND THERAPEUTICS MARKET, BY GEOGRAPHICAL REGIONS

20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. mRNA Vaccine and Therapeutics Market: Distribution by Geographical Regions, 2020, 2024 and 2035
20.3.1. mRNA Vaccine and Therapeutics Market in North America, till 2035
20.3.1.1. mRNA Vaccine and Therapeutics Market in the US, till 2035
20.3.1.2. mRNA Vaccine and Therapeutics Market in Canada, till 2035
20.3.2. mRNA Vaccine and Therapeutics Market in Europe, till 2035
20.3.2.1. mRNA Vaccine and Therapeutics Market in Germany, till 2035
20.3.2.2. mRNA Vaccine and Therapeutics Market in the UK, till 2035
20.3.2.3. mRNA Vaccine and Therapeutics Market in France, till 2035
20.3.2.4. mRNA Vaccine and Therapeutics Market in Italy, till 2035
20.3.2.5. mRNA Vaccine and Therapeutics Market in Spain, till 2035
20.3.2.6. mRNA Vaccine and Therapeutics Market in Belgium, till 2035
20.3.3. mRNA Vaccine and Therapeutics Market in Aisa-Pacific, till 2035
20.3.3.1. mRNA Vaccine and Therapeutics Market in China, till 2035
20.3.3.2. mRNA Vaccine and Therapeutics Market in India, till 2035
20.3.3.3. mRNA Vaccine and Therapeutics Market in Japan, till 2035
20.3.3.4. mRNA Vaccine and Therapeutics Market in Philippines, till 2035
20.3.3.5. mRNA Vaccine and Therapeutics Market in Australia, till 2035
20.3.4. mRNA Vaccine and Therapeutics Market in Latin America, till 2035
20.3.4.1. mRNA Vaccine and Therapeutics Market in Brazil, till 2035
20.3.5. mRNA Vaccine and Therapeutics Market in Rest of the World, till 2035
20.4. Data Triangulation and Validation

21. CONCLUSION

22. EXECUTIVE INSIGHTS

22.1. Chapter Overview
22.2. Canvax
22.2.1. Company Snapshot
22.2.2. Interview Transcript: Bernardo Jose Gómez Fernández (Business Development Manager)
22.3. eTheRNA
22.3.1. Company Snapshot
22.3.2. Interview Transcript: David Ricketts (Senior Director, Business Development)
22.4. GC Biopharma
22.4.1. Company Snapshot
22.4.2. Interview Transcript: Jaehoon Moon (Team Leader)

23. APPENDIX 1: TABULATED DATA24. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

LIST OF FIGURES

Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Secondary Research: Data Sources
Figure 3.1 Lessons Learnt from Past Recessions
Figure 4.1 Executive Summary: Market Landscape
Figure 4.2 Executive Summary: Clinical Trial Analysis
Figure 4.3 Executive Summary: Partnerships and Collaborations
Figure 4.4 Executive Summary: Funding and Investment Analysis
Figure 4.5 Executive Summary: Patent Analysis
Figure 4.6 Executive Summary: Market Forecast and Opportunity Analysis
Figure 5.1 Historical Evolution of mRNA
Figure 5.2 Key Applications of mRNA Therapeutics
Figure 6.1 mRNA Vaccine and Therapeutics: Distribution by Phase of Development
Figure 6.2 mRNA Vaccine and Therapeutics: Distribution by Type of Drug Candidate
Figure 6.3 mRNA Vaccine and Therapeutics: Distribution by Therapeutic Area
Figure 6.4 mRNA Vaccine and Therapeutics: Distribution by Phase of Development and Therapeutic Area
Figure 6.5 mRNA Vaccine and Therapeutics: Distribution by Type of Delivery System
Figure 6.6 mRNA Vaccine and Therapeutics: Distribution by Type of Molecule Encoded
Figure 6.7 mRNA Vaccine and Therapeutics: Distribution by Route of Administration
Figure 6.8 mRNA Vaccine and Therapeutics: Distribution by Therapeutic Area and Route of Administration
Figure 6.9 mRNA Vaccine and Therapeutics: Distribution by Phase of Development, Therapeutic Area and Route of Administration
Figure 7.1 mRNA Vaccine and Therapeutics Developers: Distribution by Year of Establishment
Figure 7.2 mRNA Vaccine and Therapeutics Developers: Distribution by Company Size
Figure 7.3 mRNA Vaccine and Therapeutics Developers: Distribution by Location of Headquarters
Figure 7.4 Key Players: Distribution by Number of Drug Candidates
Figure 7.5 Key Players: Distribution by Phase of Development
Figure 7.6 Key Players: Distribution by Therapeutic Area
Figure 8.1 Company Competitiveness Analysis: mRNA Vaccine and Therapeutics Developers based in North America
Figure 8.2 Company Competitiveness Analysis: mRNA Vaccine and Therapeutics Developers based in Europe
Figure 8.3 Company Competitiveness Analysis: mRNA Vaccine and Therapeutics Developers based in Asia-Pacific and Rest of the World
Figure 10.1 Big Pharma Players: Distribution of Top Pharmaceutical Companies
Figure 10.2 Big Pharma Players: Distribution by Portfolio Diversity
Figure 10.3 Big Pharma Players: Distribution by Phase of Development
Figure 10.4 Big Pharma Players: Distribution by Target Therapeutic Area
Figure 10.5 Spider Web Analysis: Amgen
Figure 10.6 Spider Web Analysis: AstraZeneca
Figure 10.7 Spider Web Analysis: Bayer
Figure 10.8 Spider Web Analysis: BioNTech
Figure 10.9 Spider Web Analysis: Eli Lilly
Figure 10.10 Spider Web Analysis: Gilead Sciences
Figure 10.11 Spider Web Analysis: GlaxoSmithKline
Figure 10.12 Spider Web Analysis: Merck
Figure 10.13 Spider Web Analysis: Moderna
Figure 10.14 Spider Web Analysis: Novartis
Figure 10.15 Spider Web Analysis: Novo Nordisk
Figure 10.16 Spider Web Analysis: Pfizer
Figure 10.17 Spider Web Analysis: Roche
Figure 10.18 Spider Web Analysis: Sanofi
Figure 10.19 Spider Web Analysis: Takeda
Figure 11.1 Startup-Health Indexing: Distribution by Location of Headquarters
Figure 11.2 Startup-Health Indexing: Distribution by Supplier Strength
Figure 11.3 Startup-Health Indexing: Distribution by Pipeline Maturity
Figure 11.4 Startup-Health Indexing: Distribution by Pipeline Strength
Figure 11.5 Startup-Health Indexing: Distribution by Financial Investments
Figure 11.6 Startup-Health Indexing: Distribution by Partnership Activity
Figure 11.7 Start-up Health Indexing: Roots Analysis Perspective
Figure 11.8 Start-up Health Indexing: Leading Companies
Figure 12.1 Clinical Trial Analysis: Distribution by Trial Registration Year, since 2017
Figure 12.2 Clinical Trial Analysis: Distribution by Trial Status
Figure 12.3 Clinical Trial Analysis: Distribution by Trial Phase
Figure 12.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Figure 12.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase
Figure 12.6 Clinical Trial Analysis: Distribution by Trial Status and Trial Phase
Figure 12.7 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year
Figure 12.8 Clinical Trial Analysis: Distribution by Study Design
Figure 12.9 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 12.10 Most Active Players: Distribution by Number of Registered Trials
Figure 12.11 Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 12.12 Clinical Trial Analysis: Distribution by Number of Registered Trials and Geography
Figure 12.13 Clinical Trial Analysis: Distribution by Number of Registered Trials, Trial Status and Geography
Figure 12.14 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Geography
Figure 13.1 Partnerships and Collaborations: Cumulative Year-wise Trend, since 2013
Figure 13.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 13.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 13.4 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 13.5 Partnerships and Collaborations: Distribution by Type of Partnership and Therapeutic Area
Figure 13.6 Most Active Players: Distribution by Number of Partnerships
Figure 13.7 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 13.8 Partnerships and Collaborations: Local and International Agreements
Figure 14.1 Funding and Investment Analysis: Cumulative Year-wise Trend, since 2013
Figure 14.2 Funding and Investment Analysis: Distribution of Amount Invested, since 2013 (USD Million)
Figure 14.3 Funding and Investment Analysis: Distribution of Funding Instances by Type of Funding
Figure 14.4 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 14.5 Funding and Investment Analysis: Distribution by Year and Type of Funding
Figure 14.6 Funding and Investment Analysis: Distribution of Funding Instances and Amount Invested by Therapeutic Area
Figure 14.7 Funding and Investment Analysis: Distribution of Funding Instances and Amount Invested by Region
Figure 14.8 Funding and Investment Analysis: Distribution of Funding Instances by Country
Figure 14.9 Most Active Players: Distribution by Number of Funding Instances
Figure 14.10 Most Active Players: Distribution by Total Amount Raised (USD Million)
Figure 14.11 Most Active Investors: Distribution by Number of Funding Instances
Figure 14.12 Funding and Investment Analysis: Distribution of Amount Invested by Year and Type of Funding
Figure 15.1 Patent Analysis: Distribution by Type of Patent
Figure 15.2 Patent Analysis: Distribution by Patent Publication Year, since 2016
Figure 15.3 Patent Analysis: Cumulative Distribution of Granted Patents by Publication Year, since 2016
Figure 15.4 Patent Analysis: Cumulative Distribution of Patent Applications by Publication Year, since 2016
Figure 15.5 Patent Analysis: Distribution of Granted Patents and Patent Applications by Publication Year, since 2016
Figure 15.6 Patent Analysis: Cumulative Distribution of Patents by Publication Year and Type of Applicant, since 2016
Figure 15.7 Patent Analysis: Distribution by Patent Issuing Authority
Figure 15.8 Patent Analysis: Distribution by Patent Age
Figure 15.9 Patent Analysis: Distribution by CPC Sections
Figure 15.10 Patent Analysis: Leading Industry Players
Figure 15.11 Patent Analysis: Leading Non-Industry Players
Figure 15.12 Leading Inventors: Distribution by Number of Patents
Figure 15.13 Patent Benchmarking: Distribution of Leading Industry Players by Patent Characteristics (CPC Codes)
Figure 15.14 Patent Analysis: Patent Valuation
Figure 16.1 mRNA Vaccine and Therapeutics: Market Drivers
Figure 16.2 mRNA Vaccine and Therapeutics: Market Restraints
Figure 16.3 mRNA Vaccine and Therapeutics: Market Opportunities
Figure 16.4 mRNA Vaccine and Therapeutics: Market Challenges
Figure 17.1 Global mRNA Vaccine and Therapeutics Market, till 2035 (USD Million)
Figure 17.2 Global mRNA Vaccine and Therapeutics Market, till 2035: Conservative Scenario (USD Million)
Figure 17.3 Global mRNA Vaccine and Therapeutics Market, till 2035: Optimistic Scenario (USD Million)
Figure 18.1 mRNA Vaccine and Therapeutics Market: Distribution by Application Area, 2024, 2028 and 2035
Figure 18.2 mRNA Vaccine and Therapeutics Market for COVID-19, till 2035 (USD Million)
Figure 18.3 mRNA Vaccine and Therapeutics Market for Other Indications, till 2035 (USD Million)
Figure 19.1 mRNA Vaccine and Therapeutics Market: Distribution by Target Disease Indication, 2026, 2030 and 2035
Figure 19.2 mRNA Vaccine and Therapeutics Market for Influenza, till 2035 (USD Million)
Figure 19.3 mRNA Vaccine and Therapeutics Market for Respiratory Syncytial Virus Infection, till 2035 (USD Million)
Figure 19.4 mRNA Vaccine and Therapeutics Market for Cytomegalovirus Disease, till 2035 (USD Million)
Figure 20.1 mRNA Vaccine and Therapeutics Market: Distribution by Geographical Regions, 2020, 2024 and 2035
Figure 20.2 mRNA Vaccine and Therapeutics Market in North America, till 2035 (USD Million)
Figure 20.3 mRNA Vaccine and Therapeutics Market in the US, till 2035 (USD Million)
Figure 20.4 mRNA Vaccine and Therapeutics Market in Canada, till 2035 (USD Million)
Figure 20.5 mRNA Vaccine and Therapeutics Market in Europe, till 2035 (USD Million)
Figure 20.6 mRNA Vaccine and Therapeutics Market in Germany, till 2035 (USD Million)
Figure 20.7 mRNA Vaccine and Therapeutics Market in the UK, till 2035 (USD Million)
Figure 20.8 mRNA Vaccine and Therapeutics Market in France, till 2035 (USD Million)
Figure 20.9 mRNA Vaccine and Therapeutics Market in Italy, till 2035 (USD Million)
Figure 20.10 mRNA Vaccine and Therapeutics Market in Spain, till 2035 (USD Million)
Figure 20.11 mRNA Vaccine and Therapeutics Market in Belgium, till 2035 (USD Million)
Figure 20.12 mRNA Vaccine and Therapeutics Market in Aisa-Pacific, till 2035 (USD Million)
Figure 20.13 mRNA Vaccine and Therapeutics Market in China, till 2035 (USD Million)
Figure 20.14 mRNA Vaccine and Therapeutics Market in India, till 2035 (USD Million)
Figure 20.15 mRNA Vaccine and Therapeutics Market in Japan, till 2035 (USD Million)
Figure 20.16 mRNA Vaccine and Therapeutics Market in Philippines, till 2035 (USD Million)
Figure 20.17 mRNA Vaccine and Therapeutics Market in Australia, till 2035 (USD Million)
Figure 20.18 mRNA Vaccine and Therapeutics Market in Latin America, till 2035 (USD Million)
Figure 20.19 mRNA Vaccine and Therapeutics Market in Brazil, till 2035 (USD Million)
Figure 20.20 mRNA Vaccine and Therapeutics Market in Rest of the World, till 2035 (USD Million)
Figure 21.1 Concluding Remarks: Overall Market Landscape
Figure 21.2 Concluding Remarks: Partnerships and Collaborations
Figure 21.3 Concluding Remarks: Funding and Investment Analysis
Figure 21.4 Concluding Remarks: Clinical Trial Analysis
Figure 21.5 Concluding Remarks: Patent Analysis
Figure 21.6 Concluding Remarks: Market Forecast and Opportunity Analysis

LIST OF TABLES

Table 6.1 mRNA Vaccine and Therapeutics: Overall Market Landscape
Table 6.2 mRNA Vaccine and Therapeutics: Information on Type of Delivery System
Table 6.3 mRNA Vaccine and Therapeutics: Information on Type of Molecule Encoded
Table 6.4 mRNA Vaccine and Therapeutics: Information on Route of Administration
Table 7.1 mRNA Vaccine and Therapeutics Developers: List of Companies
Table 9.1 mRNA Vaccine and Therapeutics Developers: List of Companies Profiled
Table 9.2 Arcturus Therapeutics: Company Overview
Table 9.3 Arcturus Therapeutics: Pipeline Overview
Table 9.4 Arcturus Therapeutics: Recent Developments and Future Outlook
Table 9.5 BioNTech: Company Overview
Table 9.6 BioNTech: Pipeline Overview
Table 9.7 BioNTech: Recent Developments and Future Outlook
Table 9.8 CureVac: Company Overview
Table 9.9 CureVac: Pipeline Overview
Table 9.10 CureVac: Recent Developments and Future Outlook
Table 9.11 Ethris: Company Overview
Table 9.12 Ethris: Pipeline Overview
Table 9.13 Ethris: Recent Developments and Future Outlook
Table 9.14 Immorna: Company Overview
Table 9.15 Immorna: Cancer Biomarker Testing Solutions Portfolio
Table 9.16 Immorna: Recent Developments and Future Outlook
Table 9.17 Moderna: Company Overview
Table 9.18 Moderna: Pipeline Overview
Table 9.19 Moderna: Recent Developments and Future Outlook
Table 9.20 Providence Therapeutics: Company Overview
Table 9.21 Providence Therapeutics: Pipeline Overview
Table 9.22 Providence Therapeutics: Recent Developments and Future Outlook
Table 9.23 Suzhou Abogen Biosciences: Company Overview
Table 9.24 Suzhou Abogen Biosciences: Pipeline Overview
Table 9.25 Gennova Biopharmaceuticals: Company Overview
Table 9.26 Gennova Biopharmaceuticals: Pipeline Overview
Table 9.27 Innovac Therapeutics: Company Overview
Table 9.28 Innovac Therapeutics: Pipeline Overview
Table 9.29 Kernal Biologics: Company Overview
Table 9.30 Kernal Biologics: Pipeline Overview
Table 9.31 Pantherna Therapeutics: Company Overview
Table 9.32 Pantherna Therapeutics: Pipeline Overview
Table 9.33 pHion Therapeutics: Company Overview
Table 9.34 pHion Therapeutics: Pipeline Overview
Table 9.35 Recode Therapeutics: Company Overview
Table 9.36 Recode Therapeutics: Pipeline Overview
Table 9.37 Rejuvenation Technologies: Company Overview
Table 9.38 Rejuvenation Technologies: Pipeline Overview
Table 9.39 RNACure: Company Overview
Table 9.40 RNACure: Pipeline Overview
Table 9.41 RNAimmune: Company Overview
Table 9.42 RNAimmune: Pipeline Overview
Table 9.43 Strand Therapeutics: Company Overview
Table 9.44 Strand Therapeutics: Pipeline Overview
Table 9.45 Turn Biotechnologies: Company Overview
Table 9.46 Turn Biotechnologies: Pipeline Overview
Table 9.47 Walvax: Company Overview
Table 9.48 Walvax: Pipeline Overview
Table 9.49 Ziphius Vaccines: Company Overview
Table 9.50 Ziphius Vaccines: Pipeline Overview
Table 11.1 mRNA Vaccine and Therapeutics Start-ups: Information on Location of Headquarters
Table 13.1 mRNA Vaccine and Therapeutics: List of Partnerships and Collaborations
Table 13.2 mRNA Vaccine and Therapeutics: Information on Type of Agreement (Country and Region), since 2013
Table 14.1 mRNA Vaccine and Therapeutics: List of Funding and Investments
Table 15.1 Patent Analysis: Top CPC Sections
Table 15.2 Patent Analysis: Top CPC Symbols
Table 15.3 Patent Analysis: Top CPC
Table 15.4 Patent Portfolio: Summary of Benchmarking Analysis
Table 15.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 15.6 Patent Portfolio: List of Leading Patents (by Highest Relative Valuation)
Table 17.1 mRNA Vaccine and Therapeutics: Expected Launch Year of Advance Stage Drug Candidates
Table 22.1 eTheRNA: Key Highlights
Table 23.1 mRNA Vaccine and Therapeutics: Distribution by Phase of Development
Table 23.2 mRNA Vaccine and Therapeutics: Distribution by Type of Drug Candidate
Table 23.3 mRNA Vaccine and Therapeutics: Distribution by Therapeutic Area
Table 23.4 mRNA Vaccine and Therapeutics: Distribution by Phase of Development and Therapeutic Area
Table 23.5 mRNA Vaccine and Therapeutics: Distribution by Type of Delivery System Used
Table 23.6 mRNA Vaccine and Therapeutics: Distribution by Type of Molecule Encoded
Table 23.7 mRNA Vaccine and Therapeutics: Distribution by Route of Administration
Table 23.8 mRNA Vaccine and Therapeutics: Distribution by Therapeutic Area and Route of Administration
Table 23.9 mRNA Vaccine and Therapeutics Developers: Distribution by Year of Establishment
Table 23.10 mRNA Vaccine and Therapeutics Developers: Distribution by Company Size
Table 23.11 mRNA Vaccine and Therapeutics Developers: Distribution by Location of Headquarters
Table 23.12 Key Players: Distribution by Number of Drug Candidates
Table 23.13 Key Players: Distribution by Phase of Development
Table 23.14 Key Players: Distribution by Therapeutic Area
Table 23.15 Startup-Health Indexing: Distribution by Location of Headquarters
Table 23.16 Startup-Health Indexing: Distribution by Supplier Strength
Table 23.17 Startup-Health Indexing: Distribution by Pipeline Maturity
Table 23.18 Startup-Health Indexing: Distribution by Pipeline Strength
Table 23.19 Startup-Health Indexing: Distribution by Financial Investments
Table 23.20 Startup-Health Indexing: Distribution by Partnership Activity
Table 23.21 Clinical Trial Analysis: Distribution by Trial Registration Year, since 2017
Table 23.22 Clinical Trial Analysis: Distribution by Trial Status
Table 23.23 Clinical Trial Analysis: Distribution by Trial Phase
Table 23.24 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Table 23.25 Clinical Trial Analysis: Distribution by Trial Status and Trial Phase
Table 23.26 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year
Table 23.27 Clinical Trial Analysis: Distribution by Study Design
Table 23.28 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 23.29 Most Active Players: Distribution by Number of Registered Trials
Table 23.30 Clinical Trial Analysis: Distribution by Therapeutic Area
Table 23.31 Clinical Trial Analysis: Distribution by Number of Registered Trials and Geography
Table 23.32 Clinical Trial Analysis: Distribution by Number of Registered Trials, Trial Status and Geography
Table 23.33 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Geography
Table 23.34 Partnerships and Collaborations: Cumulative Year-wise Trend, since 2013
Table 23.35 Partnerships and Collaborations: Distribution by Type of Partnership
Table 23.36 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 23.37 Most Active Players: Distribution by Number of Partnerships
Table 23.38 Partnerships and Collaborations: Local and International Agreements
Table 23.39 Funding and Investment Analysis: Cumulative Year-wise Trend, since 2015
Table 23.40 Funding and Investment Analysis: Distribution of Amount Invested, since 2015 (USD Million)
Table 23.41 Funding and Investment Analysis: Distribution of Funding Instances by Type of Funding
Table 23.42 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Table 23.43 Funding and Investment Analysis: Distribution by Year and Type of Funding
Table 23.44 Funding and Investment Analysis: Distribution of Funding Instances and Amount Invested by Therapeutic Area
Table 23.45 Funding and Investment Analysis: Distribution of Funding Instances and Amount Invested by Region
Table 23.46 Funding and Investment Analysis: Distribution of Funding Instances by Country
Table 23.47 Most Active Players: Distribution by Number of Funding Instances
Table 23.48 Most Active Players: Distribution by Total Amount Raised (USD Million)
Table 23.49 Most Active Investors: Distribution by Number of Funding Instances
Table 23.50 Patent Analysis: Distribution by Type of Patent
Table 23.51 Patent Analysis: Cumulative Distribution by Patent Publication Year, since 2016
Table 23.52 Patent Analysis: Distribution of Granted Patents by Publication Year, since 2016
Table 23.53 Patent Analysis: Distribution of Patent Applications by Publication Year, since 2016
Table 23.54 Patent Analysis: Distribution by Granted Patents and Patent Applications by Publication Year, since 2016
Table 23.55 Patent Analysis: Distribution of Patents by Publication Year and Type of Applicant, since 2016
Table 23.56 Patent Analysis: Distribution by Patent Issuing Authority
Table 23.57 Patent Analysis: Distribution by Patent Age
Table 23.58 Patent Analysis: Leading Industry Players
Table 23.59 Patent Analysis: Leading Non-Industry Players
Table 23.60 Leading Inventors: Distribution by Number of Patents
Table 23.61 Patent Analysis: Valuation Analysis
Table 23.62 Global mRNA Therapeutics and Vaccines Market, Historical Trends, since 2020 (USD Million)
Table 23.63 Global mRNA Therapeutics and Vaccines Market, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.64 mRNA Therapeutics and Vaccines Market: Distribution by Application Area, 2020, 2026 and 2035 (USD Million)
Table 23.65 mRNA Therapeutics and Vaccines Market for COVID-19, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.66 mRNA Therapeutics and Vaccines Market for Other Indications, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.67 mRNA Therapeutics and Vaccines Market: Distribution by Target Disease Indication, 2026, 2030 and 2035 (USD Million)
Table 23.68 mRNA Therapeutics and Vaccines Market for Influenza, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.69 mRNA Therapeutics and Vaccines Market for Respiratory Syncytial Virus Infection, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.70 mRNA Therapeutics and Vaccines Market for Cytomegalovirus Disease, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.71 mRNA Therapeutics and Vaccines Market: Distribution by Geographical Regions, 2020, 2024 and 2035 (USD Million)
Table 23.72 mRNA Therapeutics and Vaccines Market in North America, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.73 mRNA Therapeutics and Vaccines Market in the US, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.74 mRNA Therapeutics and Vaccines Market in Canada, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.75 mRNA Therapeutics and Vaccines Market in Europe, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.76 mRNA Therapeutics and Vaccines Market in Germany, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.77 mRNA Therapeutics and Vaccines Market in the UK, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.78 mRNA Therapeutics and Vaccines Market in France, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.79 mRNA Therapeutics and Vaccines Market in Italy, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.80 mRNA Therapeutics and Vaccines Market in Spain, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.81 mRNA Therapeutics and Vaccines Market in Belgium, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.82 mRNA Therapeutics and Vaccines Market in Asia-Pacific, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.83 mRNA Therapeutics and Vaccines Market in China, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.84 mRNA Therapeutics and Vaccines Market in India, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.85 mRNA Therapeutics and Vaccines Market in Japan, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.86 mRNA Therapeutics and Vaccines Market in Philippines, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.87 mRNA Therapeutics and Vaccines Market in Australia, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.88 mRNA Therapeutics and Vaccines Market in Latin America, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.89 mRNA Therapeutics and Vaccines Market in Brazil, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 23.90 mRNA Therapeutics and Vaccines Market in Rest of the World, till 2035, Conservative, Base and Optimistic Scenarios (USD Million)

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

Arcturus Therapeutics
BioNTech
CureVac
Ethris
IMMORNA
Moderna
Providence Therapeutics
RNACure
Suzhou Abogen Biosciences
Turn Biotechnologies
Gennova
Innovac Therapeutics
Kernal Biologics
Pantherna Therapeutics
pHion Therapeutics
Recode Therapeutics
Rejuvenation Technologies
RNAimmune
Strand Therapeutics
Walvax
Ziphius Vaccines

Methodology

LOADING...

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€4556EUR$4,799USD£3,820GBP
SITE LICENSE PDF	The product is a PDF.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€6644EUR$6,999USD£5,571GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€17086EUR$17,999USD£14,328GBP